New drug aims to shrink fatty liver in early trial
NCT ID NCT06947304
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-stage study tests a drug called miricorilant in 8 people with MASH, a type of fatty liver disease linked to metabolism. The goal is to see if the drug can lower the amount of new fat the liver makes and reduce overall liver fat after 6 weeks. Participants must have certain liver enzyme levels or a prior liver biopsy showing specific damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Missouri
Columbia, Missouri, 65211, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single pill tackle both fatty liver and diabetes?
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- 10-Year quest to uncover fatty Liver's hidden toll in china
- Can a single gene therapy injection reverse fatty liver disease?
- Navy beans take on fatty liver: a diet swap put to the test
- Can a promising NAFLD drug safely mix with other medicines? a trial seeks answers